Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27973
Abstract: Adoption of molecular classification in endometrial cancer (EC) into clinical practice remains challenging due to complexity in coordination of multiple assays. We aimed to develop a simple molecular technique to classify ECs into four subgroups… read more here.
Keywords: molecular classification; endometrial cancers; sequencing panel; classification endometrial ... See more keywords
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
Sign Up to like & getrecommendations! Published in 2018 at "Modern Pathology"
DOI: 10.1038/s41379-018-0172-x
Abstract: Mismatch repair-deficient endometrial cancers have a high somatic mutation burden, suggesting that patients with these tumors may benefit from immunotherapy. Elucidating the immune suppressive mechanisms of mismatch repair-deficient endometrial cancers is fundamental to developing future… read more here.
Keywords: immune; deficient endometrial; repair deficient; mismatch repair ... See more keywords
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-58183-w
Abstract: Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with CCNE1-amplification are often resistant to standard treatment and represent an unmet clinical need. Synthetic-lethal screening identified loss of the CDK1 regulator, PKMYT1, as synthetically lethal with CCNE1-amplification.… read more here.
Keywords: ccne1; ovarian endometrial; pkmyt1; endometrial cancers ... See more keywords
Mirenas against malignancy: an alternative to operative management
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Obstetrics and Gynaecology"
DOI: 10.1080/01443615.2018.1444395
Abstract: Abstract Background: Complex atypical hyperplasia is a recognised precursor to endometrial cancer, the most common gynaecological cancer of the Western World, with hysterectomy being the first line of management. With the increasing elderly population size… read more here.
Keywords: treatment; management; malignancy; mirena coil ... See more keywords
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac179
Abstract: OBJECTIVES Human epidermal growth factor receptor 2 (HER2) status in endometrial cancer is usually determined by immunohistochemistry and/or in situ hybridization. We employed a novel HER2 gene protein assay (GPA) to simultaneously assesses HER2 gene… read more here.
Keywords: her2 status; her2 gene; her2; endometrial cancers ... See more keywords
Abstract 1242: Ornithine decarboxylase as a therapeutic target in endometrial cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1242
Abstract: Endometrial cancer is the 4th most common cancer and the 6th deadliest cancer in US women. The American Cancer Society estimates there will be 60,050 new endometrial cancers in 2016, an increase of more than… read more here.
Keywords: ornithine decarboxylase; endometrial cancer; cancer; endometrial cancers ... See more keywords
Abstract 6522: Improved detection of low frequency mutations in ovarian and endometrial cancers by utilizing a highly accurate sequencing platform
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6522
Abstract: Ovarian and endometrial cancers come within the top-4 for incident cancers as well as deaths in North American women. Cure rates have not improved in 30 years as high-grade subtypes continue to be diagnosed in… read more here.
Keywords: ovarian endometrial; endometrial cancers; accurate sequencing; highly accurate ... See more keywords
Abstract IA002: Management of newly diagnosed endometrial cancers and molecular classification
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.endo24-ia002
Abstract: In the past 50 years, the treatment of this cancer has evolved from a regimen of preoperative radiation therapy followed by hysterectomy, to individualized management consisting of surgical treatment with or without additional therapy depending… read more here.
Keywords: cancer; newly diagnosed; management newly; endometrial cancers ... See more keywords
The Role of Statins in the Prevention of Ovarian and Endometrial Cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer prevention research"
DOI: 10.1158/1940-6207.capr-22-0374
Abstract: Ovarian and endometrial cancers are the most common gynecologic malignancies and emerging evidence suggests that lipid metabolism and subsequent inflammation are important etiologic factors for both tumors. Statins (HMG-CoA reductase inhibitors) are the most widely… read more here.
Keywords: ovarian endometrial; endometrial cancers; role; prevention ... See more keywords
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359251392106
Abstract: Synthetic lethality (SL) is a promising therapeutic concept that relies on the indirect targeting of vulnerabilities acquired through genetic mutations. Ovarian and endometrial cancers frequently exhibit mutations in the breast cancer (BRCA), phosphatase and tensin… read more here.
Keywords: lethality; ovarian endometrial; synthetic lethality; endometrial cancers ... See more keywords
Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.5510
Abstract: 5510 Background: Single agent aromatase inhibitor (AI) therapy is associated with limited clinical activity in ovarian cancer (OC) and endometrial cancers (EC). AI therapy was associated with a progression free survival (PFS) at 12 weeks… read more here.
Keywords: relapsed positive; ribociclib letrozole; endometrial cancers; trial ... See more keywords